Stefano Gelibter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Stefano Gelibter has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Roberto Furlan
Vita-Salute San Raffaele University, Milan, Italy
5 shared publications - Alessandra Mandelli
Clinical Neuroimmunology Unit, Institute of Experimental Neurology, Division of Neuroscience, IRCCS Ospedale San Raffaele, and Vita e Salute San Raffaele University , Milan 20132
3 shared publications Alessandra Protti
Department of Neurosciences, Neurology and Stroke Unit Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda Milan Italy
3 shared publications- Annamaria Finardi
San Raffaele Scientific Institute
3 shared publications Fiammetta Pirro
ASST Grande Ospedale Metropolitano Niguarda, Neurology, Department of Neurosciences, Piazza Ospedale Maggiore 3, Milan 20162, Italy
3 shared publications- Giulia Marostica
San Raffaele Scientific Institute
3 shared publications
Latest Publications
- Open Access
- 18 November 2024
- Published by Wiley in European Journal of Neurology
- Vol. 32 (1) , e16547
Do immune checkpoint inhibitors affect the course of multiple sclerosis? A systematic review and meta‐analysis
Background and purpose: Elderly people with multiple sclerosis (pwMS) present higher probability of malignancies. Immune checkpoint inhibitors (ICIs) improve cancer prognosis but pose risk of disease flares in people with pre‐existing autoimmune conditions, including MS. Data addressing the impact of ICIs on MS are scarce. This systematic review and meta‐analysis evaluates the effects of ICIs on MS disease activity.Methods: A systematic literature search in Google Scholar and PubMed, following PRISMA 2020 guidelines, identified five observational studies. Data on clinical and neuroradiological outcomes were analyzed using random‐effects models.Results: The clinical activity meta‐analysis included 90 pwMS undergoing ICI therapy (median follow‐up = 0.62–1.85 years, 103.74 patient‐years). The pooled relapse rate was 5.45 per 100 patient‐years (95% confidence interval [CI] = 1.86–14.92). Median time to relapse was 1 month after the ICI start (range = 0.4–6 months). No relapse occurred after 58 years. The neuroradiological activity meta‐analysis was conducted on 36 pwMS (median magnetic resonance imaging [MRI] follow‐up = 0.75–1.85 years, 41.94 patient‐years). The pooled new MRI lesion rate was 24.9 per 100 patient‐years (95% CI = 10.9–47.3), with median time to new MRI lesions of 3 months (range = 1–6 months). In 80% of cases, disease‐modifying treatment (DMT) was suspended at ICI initiation.Conclusions: We found a low relapse rate in pwMS following ICI treatment, with no events in older pwMS. The risk of neuroradiological activity appears higher, but mainly occurs in pwMS who discontinued DMT. All events occurred within the first 6 months of ICI therapy. These conclusions are based on small observational studies, highlighting the urgent need for further research on this topic.
- 18 November 2024
- Published by Wiley in European Journal of Neurology
- Vol. 32 (1) , e16547
Open AccessDo immune checkpoint inhibitors affect the course of multiple sclerosis? A systematic review and meta‐analysis
Background and purpose: Elderly people with multiple sclerosis (pwMS) present higher probability of malignancies. Immune checkpoint inhibitors (ICIs) improve cancer prognosis but pose risk of disease flares in people with pre‐existing autoimmune conditions, including MS. Data addressing the impact of ICIs on MS are scarce. This systematic review and meta‐analysis evaluates the effects of ICIs on MS disease activity.Methods: A systematic literature search in Google Scholar and PubMed, following PRISMA 2020 guidelines, identified five observational studies. Data on clinical and neuroradiological outcomes were analyzed using random‐effects models.Results: The clinical activity meta‐analysis included 90 pwMS undergoing ICI therapy (median follow‐up = 0.62–1.85 years, 103.74 patient‐years). The pooled relapse rate was 5.45 per 100 patient‐years (95% confidence interval [CI] = 1.86–14.92). Median time to relapse was 1 month after the ICI start (range = 0.4–6 months). No relapse occurred after 58 years. The neuroradiological activity meta‐analysis was conducted on 36 pwMS (median magnetic resonance imaging [MRI] follow‐up = 0.75–1.85 years, 41.94 patient‐years). The pooled new MRI lesion rate was 24.9 per 100 patient‐years (95% CI = 10.9–47.3), with median time to new MRI lesions of 3 months (range = 1–6 months). In 80% of cases, disease‐modifying treatment (DMT) was suspended at ICI initiation.Conclusions: We found a low relapse rate in pwMS following ICI treatment, with no events in older pwMS. The risk of neuroradiological activity appears higher, but mainly occurs in pwMS who discontinued DMT. All events occurred within the first 6 months of ICI therapy. These conclusions are based on small observational studies, highlighting the urgent need for further research on this topic.
- 14 May 2024
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 391, 578368
As time goes by: Treatment challenges in elderly people with multiple sclerosis
- 14 May 2024
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 391, 578368
As time goes by: Treatment challenges in elderly people with multiple sclerosis
- 13 September 2023
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 383, 578199
Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience
- 13 September 2023
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 383, 578199
Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience
- Top Cited PapersOpen Access
- 31 January 2022
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 11 (2) , e12162
The impact of storage on extracellular vesicles: A systematic study
Mounting evidence suggests that storage has an impact on extracellular vesicles (EVs) properties. While −80°C storage is a widespread approach, some authors proposed improved storage strategies with conflicting results. Here, we designed a systematic study to assess the impact of −80°C storage and freeze‐thaw cycles on EVs. We tested the differences among eight storage strategies and investigated the possible fusion phenomena occurring during storage. EVs were collected from human plasma and murine microglia culture by size exclusion chromatography and ultracentrifugation, respectively. The analysis included: concentration, size and zeta potential (tunable resistive pulse sensing), contaminant protein assessment; flow cytometry for the analysis of two single fluorescent‐tagged EVs populations (GFP and mCherry), mixed before preservation. We found that −80°C storage reduces EVs concentration and sample purity in a time‐dependent manner. Furthermore, it increases the particle size and size variability and modifies EVs zeta potential, with a shift of EVs in size‐charge plots. None of the tested conditions prevented the observed effects. Freeze‐thaw cycles lead to an EVs reduction after the first cycle and to a cycle‐dependent increase in particle size. With flow cytometry, after storage, we observed a significant population of double‐positive EVs (GFP+‐mCherry+). This observation may suggest the occurrence of fusion phenomena during storage. Our findings show a significant impact of storage on EVs samples in terms of particle loss, purity reduction and fusion phenomena leading to artefactual particles. Depending on downstream analyses and experimental settings, EVs should probably be processed from fresh, non‐archival, samples in majority of cases.
- 31 January 2022
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 11 (2) , e12162
Top Cited PapersOpen AccessThe impact of storage on extracellular vesicles: A systematic study
Mounting evidence suggests that storage has an impact on extracellular vesicles (EVs) properties. While −80°C storage is a widespread approach, some authors proposed improved storage strategies with conflicting results. Here, we designed a systematic study to assess the impact of −80°C storage and freeze‐thaw cycles on EVs. We tested the differences among eight storage strategies and investigated the possible fusion phenomena occurring during storage. EVs were collected from human plasma and murine microglia culture by size exclusion chromatography and ultracentrifugation, respectively. The analysis included: concentration, size and zeta potential (tunable resistive pulse sensing), contaminant protein assessment; flow cytometry for the analysis of two single fluorescent‐tagged EVs populations (GFP and mCherry), mixed before preservation. We found that −80°C storage reduces EVs concentration and sample purity in a time‐dependent manner. Furthermore, it increases the particle size and size variability and modifies EVs zeta potential, with a shift of EVs in size‐charge plots. None of the tested conditions prevented the observed effects. Freeze‐thaw cycles lead to an EVs reduction after the first cycle and to a cycle‐dependent increase in particle size. With flow cytometry, after storage, we observed a significant population of double‐positive EVs (GFP+‐mCherry+). This observation may suggest the occurrence of fusion phenomena during storage. Our findings show a significant impact of storage on EVs samples in terms of particle loss, purity reduction and fusion phenomena leading to artefactual particles. Depending on downstream analyses and experimental settings, EVs should probably be processed from fresh, non‐archival, samples in majority of cases.
- 3 January 2022
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (5) , 2293-2300
Encephalopathy as a prognostic factor in adults with acute disseminated encephalomyelitis following COVID-19
Numerous reports support the possible occurrence of acute disseminated encephalomyelitis (ADEM) following COVID-19. Herein, we report a case of ADEM in a 53-year-old man 2 weeks after SARS-CoV-2 infection. We reviewed the reports of adult cases of ADEM and its variant acute necrotizing hemorrhagic leukoencephalitis (ANHLE) to check for possible prognostic factors and clinical/epidemiological peculiarities. We performed a descriptive analysis of clinical and cerebrospinal fluid data. Ordinal logistic regressions were performed to check the effect of clinical variables and treatments on ADEM/ANHLE outcomes. We also compared ADEM and ANHLE patients. We identified a total of 20 ADEM (9 females, median age 53.5 years) and 23 ANHLE (11 females, median age 55 years). Encephalopathy was present in 80% of ADEM and 91.3% of ANHLE patients. We found that the absence of encephalopathy predicts a better clinical outcome in ADEM (OR 0.027, 95% CI 0.001–0.611, p = 0.023), also when correcting for the other variables (OR 0.032, 95% CI 0.001–0.995, p = 0.05). Conversely, we identified no significant prognostic factor in ANHLE patients. ANHLE patients showed a trend towards a worse clinical outcome (lower proportion of good/complete recovery, 4.5% vs 16.7%) and higher mortality (36.4% vs 11.1%) as compared to ADEM. Compared to pre-pandemic ADEM, we observed a higher median age of people with post-COVID-19 ADEM and ANHLE, a shorter interval between infection and neurological symptoms, and a worse prognosis both in terms of high morbidity and mortality. Despite being affected by the retrospective nature of the study, these observations provide new insights into ADEM/ANHLE following SARS-CoV-2 infection.
- 3 January 2022
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (5) , 2293-2300
Encephalopathy as a prognostic factor in adults with acute disseminated encephalomyelitis following COVID-19
Numerous reports support the possible occurrence of acute disseminated encephalomyelitis (ADEM) following COVID-19. Herein, we report a case of ADEM in a 53-year-old man 2 weeks after SARS-CoV-2 infection. We reviewed the reports of adult cases of ADEM and its variant acute necrotizing hemorrhagic leukoencephalitis (ANHLE) to check for possible prognostic factors and clinical/epidemiological peculiarities. We performed a descriptive analysis of clinical and cerebrospinal fluid data. Ordinal logistic regressions were performed to check the effect of clinical variables and treatments on ADEM/ANHLE outcomes. We also compared ADEM and ANHLE patients. We identified a total of 20 ADEM (9 females, median age 53.5 years) and 23 ANHLE (11 females, median age 55 years). Encephalopathy was present in 80% of ADEM and 91.3% of ANHLE patients. We found that the absence of encephalopathy predicts a better clinical outcome in ADEM (OR 0.027, 95% CI 0.001–0.611, p = 0.023), also when correcting for the other variables (OR 0.032, 95% CI 0.001–0.995, p = 0.05). Conversely, we identified no significant prognostic factor in ANHLE patients. ANHLE patients showed a trend towards a worse clinical outcome (lower proportion of good/complete recovery, 4.5% vs 16.7%) and higher mortality (36.4% vs 11.1%) as compared to ADEM. Compared to pre-pandemic ADEM, we observed a higher median age of people with post-COVID-19 ADEM and ANHLE, a shorter interval between infection and neurological symptoms, and a worse prognosis both in terms of high morbidity and mortality. Despite being affected by the retrospective nature of the study, these observations provide new insights into ADEM/ANHLE following SARS-CoV-2 infection.
- Open Access
- 5 October 2021
- Published by Springer Nature in Research Square
Encephalopathy as a prognostic factor in adults with acute disseminated encephalomyelitis following COVID-19
Numerous reports support the possible occurrence of acute disseminated encephalomyelitis (ADEM) following COVID-19. Herein, we report a case of ADEM in a 53 years-old man two weeks after SARS-CoV-2 infection. We reviewed the reports of adult cases of ADEM and its variant acute necrotizing hemorrhagic leukoencephalitis (ANHLE) to check for possible prognostic factors and clinical/epidemiological peculiarities. We performed a descriptive analysis of clinical and cerebrospinal fluid data. Ordinal logistic regressions were performed to check the effect of clinical variables and treatments on ADEM/ANHLE outcomes. We also compared ADEM and ANHLE patients. We identified a total of 20 ADEM (9 females, median age 53.5 years) and 23 ANHLE (11 females, median age 55 years). Encephalopathy was present in 80% of ADEM and 91.3% of ANHLE patients. We found that the absence of encephalopathy predicts a better clinical outcome in ADEM (OR = 0.027, 95%CI 0.001–0.611, p = 0.023), also when correcting for the other variables (OR = 0.032, 95%CI 0.001–0.995, p = 0.05). Conversely, we identified no significant prognostic factor in ANHLE patients. ANHLE patients showed a trend towards a worse clinical outcome (lower proportion of good/complete recovery, 4.5% vs 16.7%) and higher mortality (36.4% vs 11.1%) as compared to ADEM. Compared to pre-pandemic ADEM, we observed a higher median age of people with post-COVID-19 ADEM and ANHLE, a shorter interval between infection and neurological symptoms, and a worse prognosis both in terms of high morbidity and mortality. Despite being affected by the retrospective nature of the study, these observations provide new insights into ADEM/ANHLE following SARS-CoV-2 infection.
- 5 October 2021
- Published by Springer Nature in Research Square
Open AccessEncephalopathy as a prognostic factor in adults with acute disseminated encephalomyelitis following COVID-19
Numerous reports support the possible occurrence of acute disseminated encephalomyelitis (ADEM) following COVID-19. Herein, we report a case of ADEM in a 53 years-old man two weeks after SARS-CoV-2 infection. We reviewed the reports of adult cases of ADEM and its variant acute necrotizing hemorrhagic leukoencephalitis (ANHLE) to check for possible prognostic factors and clinical/epidemiological peculiarities. We performed a descriptive analysis of clinical and cerebrospinal fluid data. Ordinal logistic regressions were performed to check the effect of clinical variables and treatments on ADEM/ANHLE outcomes. We also compared ADEM and ANHLE patients. We identified a total of 20 ADEM (9 females, median age 53.5 years) and 23 ANHLE (11 females, median age 55 years). Encephalopathy was present in 80% of ADEM and 91.3% of ANHLE patients. We found that the absence of encephalopathy predicts a better clinical outcome in ADEM (OR = 0.027, 95%CI 0.001–0.611, p = 0.023), also when correcting for the other variables (OR = 0.032, 95%CI 0.001–0.995, p = 0.05). Conversely, we identified no significant prognostic factor in ANHLE patients. ANHLE patients showed a trend towards a worse clinical outcome (lower proportion of good/complete recovery, 4.5% vs 16.7%) and higher mortality (36.4% vs 11.1%) as compared to ADEM. Compared to pre-pandemic ADEM, we observed a higher median age of people with post-COVID-19 ADEM and ANHLE, a shorter interval between infection and neurological symptoms, and a worse prognosis both in terms of high morbidity and mortality. Despite being affected by the retrospective nature of the study, these observations provide new insights into ADEM/ANHLE following SARS-CoV-2 infection.
- Open Access
- 25 August 2021
Flow cytometry data of "The impact of storage on extracellular vesicles: a systematic study" experiments
- 25 August 2021
Open AccessFlow cytometry data of "The impact of storage on extracellular vesicles: a systematic study" experiments